Pharma Mar, S.A. (BME:PHM)
Spain flag Spain · Delayed Price · Currency is EUR
80.50
+1.60 (2.03%)
Jun 27, 2025, 1:42 PM CET

Pharma Mar Company Description

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.

The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma.

The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa.

In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression.

Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Pharma Mar, S.A.
Pharma Mar logo
Country Spain
Founded 1986
Industry Biotechnology
Sector Healthcare
Employees 500
CEO Jose Fernandez Sousa-Faro

Contact Details

Address:
Avenida de los Reyes, 1
Madrid, 28770
Spain
Phone 34 91 846 60 00
Website pharmamar.com

Stock Details

Ticker Symbol PHM
Exchange Madrid Stock Exchange
Fiscal Year January - December
Reporting Currency EUR
ISIN Number ES0169501022
SIC Code 2836

Key Executives

Name Position
Jose Maria Fernandez Sousa-Faro Ph.D. Founder, Executive Chairman, Chief Executive Officer and President
Pedro Francisco Fernandez Puentes Executive Vice-Chairman
Juan Carlos-Torres Carretero Founder
María Luisa de Francia Caballero Chief Financial Officer
José Luis Moreno Martinez-Losa Head of Capital Markets and Investor Relations
Juan Gomez Pulido General Counsel and Secretary of the Board of Directors
Sandra Llamera Sanchez Global Compliance Head
Lara Vadillo Communication Director
Belén Sopesén Veramendi Ph.D. Director of Corporate Development
Luis Rupérez Cuenca Director of Human Resources and IT